-
Fernandez uncertain over Chelsea future after Champions League exit
-
Iran women's football team arrive in eastern Turkey, heading home
-
Russia slams Oscar-winning anti-Putin documentary
-
Mass burials expected for victims of Kabul drug rehab centre strike
-
Celtic keeper Schmeichel fears shoulder injury could end his career
-
Israelis shelter with pets from threat of Iran missiles
-
Deadly strikes across Mideast as Iran vows revenge on slain security chief
-
Japan, S. Korea petrochemical industry slows output on Iran war
-
Stocks extend gains, oil sinks as US, Israel, Iran press on strikes
-
Record setters Duplantis, Hodgkinson headline Torun world indoors
-
Chinese visitors to Japan plunge 45.2% in February
-
BTS light stick prices surge ahead of comeback concert
-
'Special human' Slipper to break Super Rugby appearance record
-
Brussels to unveil 'EU Inc' pan-European company status
-
Iran to hold funeral for slain security chief as it vows vengeance
-
Greenland's teenage boxers throwing punches to survive
-
TotalEnergies faces ruling in Belgian farmer climate case
-
Brazil starts to restrict minors' access to social media
-
Trespasser caught in viral hippo Moo Deng's Thai zoo pen
-
Venezuela stun USA to win politically charged World Baseball crown
-
Gilgeous-Alexander scores 40 as Thunder clinch playoff berth
-
Venezuela stun United States to win World Baseball Classic
-
Cuba vows 'unbreakable resistance' as US pressure mounts
-
Stocks extend gains and oil dips as US, Israel, Iran continue strikes
-
Iran missile fire kills two in central Israel: medics
-
Britain, Rwanda in £100m court clash over migrant deal
-
'We will wait for each one': Ukrainians greet POWs with tears and cheers
-
UN watchdog says projectile struck Iran nuclear power plant
-
Trump faces impasse over Iran war
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Former Australian Test wicketkeeper Haddin to coach NSW
-
China coach says team on right track despite Asian Cup heartache
-
Oscars audience drops, viewing figures show
-
Resilient Australia 'need to be better' in Women's Asian Cup final
-
Gio Reyna picked for US squad as Pochettino says World Cup roster still 'open'
-
Colombia, Ecuador leaders clash over bomb dropped near border
-
PSG, Real Madrid and Arsenal march into Champions League last eight
-
'Incomplete' Man City not what they once were, says Guardiola
-
US judge orders Trump admin to bring VOA employees back to work
-
White House pressure on Cuba mounts as island fights power cut
-
Arteta hails 'magical' Eze after Arsenal star sinks Leverkusen
-
Senegal stripped of AFCON title, Morocco declared champions
-
Nvidia says restarting production of China-bound chips
-
Real Madrid 'change' under Champions League spotlight: Vinicius
-
Real Madrid dump Man City out of Champions League once more
-
Clinical PSG bury Chelsea to reach Champions League quarter-finals
-
Eze rocket fires Arsenal into Champions League quarters
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
USS Gerald R. Ford: the world's biggest aircraft carrier
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
O.Krause--BTB